Today, Gargoyle Investment Advisor L.L.C. cuts position of Orthofix International NV (OFIX)

Today, Gargoyle Investment Advisor L.L.C. cuts position of Orthofix International NV (OFIX)

Gargoyle Investment Advisor L.L.C. decreased its position in shares of Orthofix International NV (NASDAQ:OFIX) by 25.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,455 shares of the medical device company’s stock after selling 3,500 shares during the period. Gargoyle Investment Advisor L.L.C.’s holdings in Orthofix International NV were worth $443,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in OFIX. American Century Companies Inc. boosted its position in shares of Orthofix International NV by 62.2% in the second quarter. American Century Companies Inc. now owns 30,275 shares of the medical device company’s stock worth $1,284,000 after buying an additional 11,605 shares during the last quarter. Bank of Montreal Can bought a new position in shares of Orthofix International NV during the second quarter worth about $456,000. Acadian Asset Management LLC boosted its position in shares of Orthofix International NV by 25.1% in the second quarter. Acadian Asset Management LLC now owns 660,196 shares of the medical device company’s stock worth $27,993,000 after buying an additional 132,537 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Orthofix International NV by 28.0% in the first quarter. Royal Bank of Canada now owns 12,913 shares of the medical device company’s stock worth $536,000 after buying an additional 2,828 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Orthofix International NV by 78.7% in the first quarter. Renaissance Technologies LLC now owns 456,379 shares of the medical device company’s stock worth $18,949,000 after buying an additional 201,020 shares during the last quarter. Institutional investors and hedge funds own 91.26% of the company’s stock.

Orthofix International NV (NASDAQ:OFIX) traded up 0.17% on Thursday, hitting $40.61. The stock had a trading volume of 133,664 shares. The company has a 50-day moving average price of $43.62 and a 200 day moving average price of $43.81. The firm’s market cap is $736.02 million. Orthofix International NV has a 52-week low of $32.25 and a 52-week high of $48.25.

Orthofix International NV (NASDAQ:OFIX) last issued its quarterly earnings results on Monday, August 1st. The medical device company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.08. Orthofix International NV had a positive return on equity of 8.50% and a negative net margin of 0.37%. The firm had revenue of $104.10 million for the quarter, compared to the consensus estimate of $102.40 million. During the same period in the prior year, the business posted $0.36 earnings per share. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. Equities analysts forecast that Orthofix International NV will post $1.41 earnings per share for the current fiscal year.

A number of brokerages have issued reports on OFIX. Zacks Investment Research cut Orthofix International NV from a “buy” rating to a “hold” rating in a research note on Tuesday. TheStreet cut Orthofix International NV from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd.

In other news, insider Michael Finegan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $45.16, for a total value of $1,129,000.00. Following the sale, the insider now directly owns 51,670 shares in the company, valued at $2,333,417.20. The sale was disclosed in a document filed with the SEC, which is available at this link. 5.10% of the stock is owned by insiders.

Orthofix International NV Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Related posts

Leave a Comment